Portfolio company Auspherix, which is meeting the urgent need for new antibiotics by developing a novel class of organogold antibacterials, has announced the appointments of Dr Richard Rutter as Chief Scientific Officer (CSO) and Dr Paul King as Head of Chemistry. Dr Neil Miller, who has been serving as Auspherix's CSO, will transition to Chief Executive Officer (CEO).
Dr Miller has served as CSO of Auspherix over the past 12 months, where he has been responsible for the Company’s antibiotic R&D programmes, having previously gained two decades of experience working at GlaxoSmithKline. As CEO, he will drive Auspherix’s novel compounds through pre-clinical development and into the clinic, as well as extend the anti-infectives company’s contacts with future potential investors and partners.
Auspherix Chairman Dr Roberto Solari said:
“Neil has provided excellent hands-on scientific leadership as CSO. His proven expertise in drug discovery has been instrumental in focusing our R&D and driving our programmes forward. As CEO I am confident that he will continue to ensure scientific progress as well as to secure the finance and partnerships needed to give our innovative organogold antibiotics the best chance of success.”